We all want to stay healthy – who doesn’t?
But with people’s lifestyle choices, including the foods we eat and how often we exercise, achieving better health sometimes feels almost impossible.
Because of this, people opt for so-called health products that promise to reverse signs of aging and return their youthful health, even though they are too good to be true.
Fortunately, there’s a new discovery that’s been proven by science to help slow down aging, increase muscle size, lose stubborn fat, and help keep you in good overall health.
It’s none other than peptides.
When it comes to anti-aging peptides, two names often come up: Ipamorelin and Tesamorelin.
You see, these peptides help increase human growth hormone (HGH) production in the body.
HGH is important in supporting normal body structure and metabolism in both kids and adults.
The big question is: which of the two should you use?
In this article, we’ll explore the benefits of tesamorelin vs. ipamorelin to help you decide which one best suits your needs.
Tesamorelin vs Ipamorelin: Mechanism of Action
Tesamorelin and ipamorelin are two of the best peptides to help with muscle growth and fat loss.
They can also help stave off diseases that may put your health at risk.
Learn more about ipamorelin vs. tesamorelin below.
Tesamorelin
Tesamorelin is a synthetic form of the growth hormone-releasing peptide with 44 amino acids developed by Theratechnologies, Inc. of Canada.
This peptide has been approved by the FDA for use to treat HIV-associated lipodystrophy or an abnormal distribution of body fat.
It works by stimulating the pituitary gland, secreting and activating growth hormone (GH).
GH then acts on the hepatocytes, where it stimulates the production of insulin-like growth factor-1 (IGF-1).
This in turn helps boost your muscle growth and fat loss.
Top Benefits of Tesamorelin
Tesamorelin has been shown in studies to help promote fat loss.
In fact, the FDA approved this peptide for the treatment of reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
A study published in the Journal of Acquired Immune Deficiency Syndromes reported that the peptide can help reduce visceral fat in HIV-infected patients by 18%.
After 12 months of using 2 mg of tesamorelin via subcutaneous injection, researchers noticed a sustained decrease in visceral adipose tissue in the test subjects.
A 12-month study of 404 HIV-infected patients with excess abdominal fat in the context of antiretroviral therapy was conducted between January 2007 and October 2008.
The study consisted of 2 sequential phases.
In the primary efficacy phase (months 0-6), patients were randomly assigned to receive tesamorelin [2 mg subcutaneous (SC) every day] or placebo in a 2:1 ratio.
In the extension phase (months 6-12), patients receiving tesamorelin were rerandomized to continue on tesamorelin (2 mg SC every day) or switch to a placebo.
VAT decreased by -10.9% (-21 cm(2)) in the tesamorelin group vs. -0.6% (-1 cm(2)) in the placebo group in the 6-month efficacy phase, P < 0.0001. Trunk fat (P < 0.001), waist circumference (P = 0.02), and waist-hip ratio (P = 0.001) improved, with no change in limb or abdominal SC fat. Insulin-like growth factor-1 increased (P < 0.001), but no change in glucose parameters was observed.
Patient rating of belly appearance distress (P = 0.02) and physician rating of belly profile (P = 0.02) were significantly improved in the tesamorelin vs. placebo-treated groups.
VAT was reduced by approximately 18% (P < 0.001) in patients continuing tesamorelin for 12 months.
The initial improvements over 6 months in VAT were rapidly lost in those switching from tesamorelin to the placebo.
Similarly, another study in The New England Journal of Medicine also showed that taking 2 mg of tesamorelin for 26 weeks can help decrease visceral fat by 15.2% and improve lipid profiles in HIV-infected patients.
The measure of visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group.
The levels of triglycerides decreased by 50 mg per deciliter and increased by 9 mg per deciliter, respectively, and the ratio of total cholesterol to HDL cholesterol decreased by 0.31 and increased by 0.21, respectively (P<0.001 for all comparisons).
Levels of total cholesterol and HDL cholesterol also improved significantly in the tesamorelin group.
Levels of IGF-I increased by 81.0% in the tesamorelin group and decreased by 5.0% in the placebo group (P<0.001).
Tesamorelin is also called a “cognitive enhancer,” as it can help patients with age-memory-related problems, improving memory and cognitive function.
A study in Archives of Neurology showed that using tesamorelin for 20 weeks improved verbal memory, executive function, and visual memory in both healthy older adults and adults with mild cognitive impairments.
Twenty weeks of GHRH administration had favorable effects on cognition in both adults with MCI and healthy older adults.
The intent-to-treat analysis indicated a favorable effect of GHRH on cognition (P=.03), which was comparable in adults with MCI and healthy older adults.
The completer analysis showed a similar pattern, with a more robust GHRH effect (P=.002).
Subsequent analyses indicated a positive GHRH effect on executive function (P=.005) and a trend showing a similar treatment-related benefit in verbal memory (P=.08).
Treatment with GHRH increased insulin-like growth factor 1 levels by 117% (P<.001), which remained within the physiological range, and reduced percent body fat by 7.4% (P<.001).
Treatment with GHRH increased fasting insulin levels within the normal range by 35% in adults with MCI (P<.001) but not in healthy adults.
Adverse events were mild and were reported by 68% of GHRH-treated adults and 36% of those who received the placebo.
Treatment with GHRH had a favorable effect on cognition (F3,125 = 5.26, P = .002), and even though the healthy adults outperformed those with MCI overall (F3,125 = 11.15, P < .001), the cognitive benefit relative to the placebo was comparable for both groups (no treatment × diagnosis interaction; P = .57).
The results of the completer analysis indicated similar GHRH benefits at weeks 10 and 20 (no interaction involving week on treatment).
Apart from that, the peptide tesamorelin is also believed to improve lipid profiles, including total cholesterol, triglyceride, and good and bad cholesterol, thanks to its GH-boosting and fat-burning properties.
HIV-infected patients who took tesamorelin for 52 weeks noticed reduced triglycerides, according to the Journal of Clinical Infectious Diseases.
In contrast to nonresponders, HIV-infected patients receiving tesamorelin with ≥8% reduction in VAT have significantly improved triglyceride levels, adiponectin levels, and preservation of glucose homeostasis over 52 weeks of treatment.
Compared with tesamorelin nonresponders, responders experienced greater mean (±SD) reduction in triglyceride levels (26 weeks: −0.6 ± 1.7 mmol/L vs −0.1 ± 1.2 mmol/L [P = .005]…
52 weeks: −0.8 ± 1.8 mmol/L vs 0.0 ± 1.1 mmol/L [P = .003]) and attenuated changes in fasting glucose levels (26 weeks: 1 ± 16 mg/dL vs 5 ± 14 mg/dL [P = .01]…
52 weeks: −1 ± 14 mg/dL vs 8 ± 17 mg/dL [P < .001]), hemoglobin A1c levels (26 weeks: 0.1 ± 0.3% vs 0.3 ± 0.4% [P < .001]…
52 weeks: 0.0 ± 0.3% vs 0.2 ± 0.5% [P = .003]), and other parameters of glucose homeostasis.
Similar patterns were seen for adiponectin levels, with significant improvement in responders vs. nonresponders. Changes in lipid levels and glucose homeostasis were significantly associated with percentage change in VAT.
In another study from PLOS ONE, patients with type 2 diabetes recorded reduced low-density lipoprotein and total cholesterol after 12 weeks of using tesamorelin.
In addition, relevant modifications in diabetes medications were similar between groups. Total cholesterol (-0.3±0.6 mmol/L) and non-HDL cholesterol (-0.3±0.5 mmol/L) significantly decreased from baseline to Week 12 in the tesamorelin 2 mg group (p<0.05 vs. placebo).
Apart from that, tesamorelin can also improve liver function.
In fact, Canadian researchers have discovered that using tesamorelin for 12 months can help to reduce not only adipose fat but also liver fat.
At baseline, VAT was positively associated with ALT (P = 0.01).
In subjects assigned to tesamorelin with baseline ALT or AST > 30 U/L, VAT responders experienced greater reductions in ALT (−8.9 ± 22.6 vs. 1.4 ± 34.7 U/L, P = 0.004) and AST (−3.8 ± 12.9 vs. 0.4 ± 22.4 U/L, P = 0.04) compared to nonresponders over 26 weeks.
This improvement among VAT responders persisted over 52 weeks even in those switched to the placebo despite a partial re-accumulation of VAT.
Twenty-six weeks after randomization to tesamorelin, ALT decreased by 8.9 ± 22.6 U/L among VAT responders, whereas it increased by 1.4 ± 34.7 U/L among VAT nonresponders (responders vs. nonresponders, P = 0.004).
Similarly, VAT responders experienced a 3.8 ± 12.9 U/L reduction in AST compared to a 0.4 ± 22.4 U/L increase among VAT nonresponders (responders vs. nonresponders, P = 0.04).
The relationship between responder status and change in ALT or AST among tesamorelin-treated patients was not modified by viral hepatitis status or clinical trial.
Thus, VAT responders with and without viral hepatitis had comparable declines in liver enzymes.
Within-group comparisons of change in transaminases at week 26 compared to baseline were significant among VAT responders (week 26 vs. 0, ALT P < 0.001, AST P < 0.001), but not among VAT nonresponders (week 26 vs. 0, ALT P = 0.71, AST P = 0.87).
Moreover, since tesamorelin can help with fat loss, it can then lower high blood sugar levels in HIV-infected patients according to several clinical trials, including one from the Annals of Pharmacotherapy.
In fact, this has been shown after 26 and 52 weeks of taking tesamorelin consistently.
In two Phase 3 clinical trials and their pooled analyses, tesamorelin was proven to significantly decrease waist circumference and visceral adipose tissue (VAT) following 26 weeks of treatment.
Both trials also demonstrated significant improvements in some subjective body image parameters.
Both studies had 26-week extension phases that confirmed maintenance of VAT improvements on treatment without adverse impact on blood glucose and lipid parameters.
52 weeks: −0.8 ± 1.8 mmol/L vs 0.0 ± 1.1 mmol/L [P = .003]) and attenuated changes in fasting glucose levels (26 weeks: 1 ± 16 mg/dL vs 5 ± 14 mg/dL [P = .01].
52 weeks: −1 ± 14 mg/dL vs 8 ± 17 mg/dL [P < .001]), hemoglobin A1c levels (26 weeks: 0.1 ± 0.3% vs 0.3 ± 0.4% [P < .001]; 52 weeks: 0.0 ± 0.3%.
Ipamorelin
Ipamorelin is a growth hormone secretagogue or growth hormone-releasing peptide (GHRP).
It is composed of five amino acids with the ability to mimic the body’s natural growth hormone.
It works by binding to ghrelin receptors located on the pituitary gland to stimulate and release growth hormone.
It does this without affecting other hormones such as cortisol, acetylcholine, aldosterone, and prolactin in the body.
With this, ipamorelin has recorded virtually no adverse side effects, making it one of the most effective and safest peptide therapy options.
Not only that, it also optimizes growth hormone longer than any other GH peptide, providing potent effects for sports performance, aging, weight loss, and chronic disease management.
Moreover, it boosts insulin levels, cell synthesis, and ghrelin levels, which help promote muscle mass and fat loss.
Top Benefits of Ipamorelin
Athletes and bodybuilders love ipamorelin. Why?
Because it has muscle-building properties that help them lose body fat while building lean muscle mass at the same time.
In fact, ipamorelin helps muscle regeneration and increases collagen production by up to 860% based on a study published by PLOS One.
Wound healing in muscles involves the deposition of collagen, but it is not known whether this is achieved by changes in the synthesis or the degradation of collagen.
We have used a reliable flooding dose method to measure collagen synthesis rate in vivo in rat abdominal muscles following surgical incisions.
Collagen synthesis rate increased by 480% and 860% on days 2 and 7, respectively after surgery in the wounded muscle compared with an undamaged area of the same muscle.
Collagen content was increased by approximately 100% on both days 2 and 7.
These results demonstrate that collagen deposition during wound healing in muscles is achieved entirely by an increase in the rate of collagen synthesis.
Ipamorelin also helps maintain healthy bones and a skeletal frame, protecting you from possible bone disorders.
In children, those who took ipamorelin for 60 days increased bone growth velocity according to The Journal of Clinical Endocrinology & Metabolism.
Six prepubertal children with GHD and growth failure received stepwise increasing s.c. doses of GHRP-2, at 0.3, 1.0, and 3.0 micrograms/kg/day, in successive 2-month treatment periods, with monitoring of overnight 12 h episodic GH secretion and toxicity measures at the end of each period.
During a fourth 2-month period, they received 3 micrograms/kg GHRP-2 together with 3 micrograms/kg s.c. GHRH.
Serum levels of IGF-I and IGFBP-3 were also measured, and stadiometer height measurements were recorded.
GHRP-2 administration produced a dosewise increase in overnight GH secretion.
GH profiles showed that the effect of GHRP-2 injections was relatively brief, with little effect upon GH secretion later in the night.
Growth velocity was higher during GHRP-2 treatment than during pre-treatment and post-treatment evaluations.
Moreover, researchers from the Department of Pharmacological Research discovered that mice given ipamorelin recorded longitudinal bone growth.
With the objective of investigating the effects on longitudinal bone growth rate (LGR), body weight (BW), and GH release, ipamorelin in different doses (0, 18, 90, and 450 microg/day) was injected s.c. three times daily for 15 days to adult female rats.
After intravital tetracycline labeling on days 0, 6, and 13, LGR was determined by measuring the distance between the respective fluorescent bands in the proximal tibia metaphysis. Ipamorelin dose-dependently increased LGR from 42 microm/day in the vehicle group to 44, 50, and 52 microm/day in the treatment groups (P<0.0001).
There was also a pronounced and dose-dependent effect on BW gain.
The treatment did not affect total IGF-I levels, IGFBPs, or serum markers of bone formation and resorption.
The responsiveness of the pituitary to a provocative i.v. dose of ipamorelin or GHRH showed that the plasma GH response was marginally reduced (P<0.03) after ipamorelin, but was unchanged after GHRH.
The peptide ipamorelin also supports digestive health and gastrointestinal function.
According to studies published in the Gut Journal, the peptide helps boost ghrelin levels, helping improve gastric motility in test subjects.
Nine healthy volunteers (four males; aged 22-35 years) underwent combined antroduodenal manometry and proximal stomach barostat study on two separate occasions at least one week apart.
Twenty minutes after the occurrence of phase III of the migrating motor complex (MMC), saline or ghrelin 40 mug was administered intravenously over 30 minutes in a double-blind, randomized, crossover fashion.
Spontaneous phase III occurred in all subjects, with a gastric origin in four.
Administration of ghrelin induced a premature phase III (12 (3) minutes, p<0.001; gastric origin in nine, p<0.05), compared with saline (95 (13) minutes, gastric origin in two).
Intraballoon volumes before infusion were similar (135 (13) v 119 (13) ml; NS) but ghrelin induced a long-lasting decrease in intraballoon volume (184 (31) v 126 (21) ml in the first 60 minutes; p<0.05).
Administration of ghrelin increased plasma levels of pancreatic polypeptide and ghrelin, but motilin, somatostatin, and glucagon levels were not altered.
Moreover, in patients who have had abdominal surgery, those given ipamorelin had improved function of their lower and upper gastrointestinal tracts.
One hundred seventeen patients were enrolled, of whom 114 patients composed the safety and modified intent-to-treat populations.
Demographic and disease characteristics were balanced between groups.
Overall incidence of any treatment-emergent adverse events was 87.5% in the ipamorelin group and 94.8% in the placebo group.
Median time to first tolerated meal was 25.3 and 32.6 h in the ipamorelin and placebo groups, respectively (p = 0.15).
Several human clinical trials and animal studies also documented ipamorelin’s cardioprotective effects, protecting people from the onset of possible heart problems.
In a study in The New England Journal of Medicine, patients with heart diseases who were given ipamoreline for three months experienced improved heart health and function, including ventricular mechanical work and cardiac output.
It reduced the size of the left ventricular chamber and increased myocardial mass in patients.
Seven patients with idiopathic dilated cardiomyopathy and moderate to severe heart failure were studied at baseline, after three months of therapy with human growth hormone, and three months after the discontinuation of growth hormone.
When administered at a dose of 14 IU per week, growth hormone doubled the serum concentrations of insulin-like growth factor I.
Growth hormone increased left ventricular wall thickness and reduced chamber size significantly.
Consequently, end-systolic wall stress (a function of both wall thickness and chamber size) fell markedly (from a mean [+/-SE] of 144+/-11 to 85+/-8 dyn per square centimeter, P<0.001).
Growth hormone improved cardiac output, particularly during exercise (from 7.4+/-0.7 to 9.7+/-0.9 liters per minute, P=0.003), and enhanced ventricular work, despite reductions in myocardial oxygen consumption (from 56+/-6 to 39+/-5 ml per minute, P=0.005) and energy production (from 1014+/-100 to 701+/-80 J per minute, P=0.002).
Thus, ventricular mechanical efficiency rose from 9+/-2 to 21+/-5 percent (P=0.006).
Growth hormone also improved clinical symptoms, exercise capacity, and the patients’ quality of life.
The changes in cardiac size and shape, systolic function, and exercise tolerance were partially reversed three months after growth hormone was discontinued.
Moreover, ipamorelin has a potent blood sugar-lowering property that can help minimize your risks of diabetic complications and other fatal conditions related to high blood sugar levels.
In fact, ipamorelin’s ability to boost GH secretion helps improve blood sugar levels in diabetic patients according to The Journal of Clinical Endocrinology & Metabolism.
Six type 1 diabetic males and six age-, sex-, and body mass index-matched control volunteers were studied.
Each subject received GHRH (100 microg iv), GHRP-6 (90 microg iv), and GHRH plus GHRP-6 on three separate days.
GH peak values were higher in DM 1 patients than in control volunteers, after GHRH (52.2+/-9.8 vs. 19.3+/-6.0 microg/L; P = 0.016), GHRP-6 (66.2+/-9.6 vs. 39.9+/-6.3 microg/L; P = 0.05), and GHRH plus GHRP-6 (81.8+/-4.4 vs. 53.7+/-8.2 microg/L; P = 0.01).
An additive GH response to combined administration of these two peptides was observed in diabetic patients.
Serum insulin-like growth factor (IGF)-1 levels were diminished in DM 1, with respect to normal subjects (145.2+/-21.5 vs. 269.7+/-42.0 microg/L; P = 0.01), whereas IGF-binding protein-3 levels were not significantly different between DM-1 and controls.
In summary, GHRP-6 is a potent stimulus for GH secretion in DM 1.
The combined administration of GHRP-6 plus GHRH constitutes the most powerful stimulus for GH secretion in DM 1.
These patients exhibit a greater GH secretory capacity than normal subjects, probably caused by a diminished tone in the IGF-1 sustained negative feedback control exerted upon somatotroph responsiveness.
Apart from that, a study in the Journal of Clinical Investigation showed that the peptide ipamorelin can also improve immune system health and function.
It does this through several ways, including the development of the thymus gland, which secrete T-cell production for the immune system.
T cells help protect your body from possible pathogens and infections that can make you feel sick.
Recombinant human growth hormone (rhGH) promotes human T cell engraftment in mice with severe combined immunodeficiency, suggesting that rhGH may have effects on T cell adhesion and migration in vivo.
rhGH induced significant human T cell adherence to both human and murine substrates via either beta 1 or beta 2 integrin molecules.
rhGH was capable of inducing significant migration of resting and activated human T cells and their subsets.
Most of the migratory response to rhGH was chemokinetic rather than chemotactic.
In vivo engraftment studies in severe combined immunodeficiency mice receiving human T cells revealed that treatment with rhGH resulted in improved thymic engraftment, whereas treatment with non-human-reactive ovine GH demonstrated no significant effects.
This data demonstrates that rhGH directly augments human T cell trafficking to peripheral murine lymphoid tissues.
rhGH appears to be capable of directly altering the adhesive and migratory capacity of human T cells to molecules of either murine or human origin.
Therefore, GH may, under either isogeneic or xenogeneic conditions, play a role in normal lymphocyte recirculation.
Not only that, but ipamorelin also supports brain health and age-related decline caused by medical conditions, such as Parkinson’s disease.
According to a study published in the Journal of Molecular Endocrinology, ipamoreline helps with Parkinson’s disease by increasing ghrelin levels in patients.
The increase in ghrelin also boosts the brain chemical dopamine, which is responsible for reward-motivated behaviors.
To identify neurons that express the ghrelin receptor [GH secretagogue receptor (GHS-R)], we generated GHS-R-IRES-tauGFP mice by gene targeting.
Neurons expressing the GHS-R exhibit green fluorescence and are clearly evident in the hypothalamus, hippocampus, cortex, and midbrain.
Using immunohistochemistry in combination with green fluorescent protein fluorescence, we identified neurons that coexpress the dopamine receptor subtype 1 (D1R) and GHS-R.
The potential physiological relevance of coexpression of these two receptors and the direct effect of ghrelin on dopamine signaling was investigated in vitro.
Activation of GHS-R by ghrelin amplifies dopamine/D1R-induced cAMP accumulation.
Intriguingly, amplification involves a switch in G protein coupling of the GHS-R from Galpha (11/q) to Galpha (i/o) by a mechanism consistent with agonist-dependent formation of GHS-R/D1R heterodimers.
Most importantly, these results indicate that ghrelin has the potential to amplify dopamine signaling selectively in neurons that coexpress D1R and GHS-R.
As a growth hormone-releasing peptide, ipamorelin can also boost GH and IGF-1 levels, improving sexual function in men and women.
It works by increasing the molecule nitric oxide, stimulating longer and harder erections in men.
In the pituitary, NO was found to increase growth hormone (GH) secretion in several in vitro and in vivo models.
Incubation of the human fetal pituitaries (21-24 wk gestation) in the presence of sodium nitroprusside (SNP; 1 mM), a NO donor, for 4 h resulted in a 50-75% increase in GH secretion, similar to the stimulatory effect evoked by growth hormone-releasing hormone (GHRH) (10 nM).
However, fetal PRL secretion was not affected by SNP.
GH release was also stimulated (40-70% increase) by SNP in 60% of the cultured GH-secreting adenomas studied.
SNP-induced GH release was inhibited in both fetal and adenomatous cells by PTI0, a NO scavenger.
The addition of cGMP (0.1-1 mM), the second messenger of multiple NO actions, enhanced fetal and adenomatous GH secretion by 55-95%. Neuronal NOS (nNOS) was expressed in normal (fetal and adult) human pituitary tissues and in GH-secreting adenomas.
Examination of its functional expression using L-arginine (1 microM) yielded a 35% increase in GH release from cultured GH-secreting adenoma.
This response was blocked by a NOS inhibitor with high selectivity for the neuronal enzyme and by a guanylyl cyclase inhibitor.
Aside from boosting GH and IGF-1 levels, the peptide also increases levels of testosterone and estrogen.
These hormones are both important in the regulation of sexual thoughts, function, and desire.
GH increased testosterone and oestradiol secretions in a dose-dependent manner.
While testosterone secretion reached the saturation point with 50 ng GH, oestradiol secretion reached the saturation point with 150 ng GH, followed by diminished secretions.
Co-administration of minimum (10 ng) effective doses of GH with minimum (25 ng) or maximum (100 ng) effective doses of oLH significantly decreased testosterone secretion.
However, an increased secretion of testosterone was observed when maximum effective doses of rGH (50 ng) and oLH (100 ng) were co-administered. Minimum effective (25 ng) or maximum effective (50 ng) doses of T3 inhibited GH-mediated secretion of testosterone in vitro.
Oestradiol concentration in the culture medium increased when either dose of rGH was co-administered with the minimum or maximum effective doses of oLH.
T3 50 ng augmented the secretion of oestradiol by Leydig cells in the presence of GH.
These results indicate that GH acts as a gonadotrophin to stimulate testosterone and oestradiol secretions by Leydig cells, and that it modulates LH or T3-induced secretion of these steroids, depending on the intensity of their stimulation.
Lastly, ipamorelin also promotes restful sleep, as it enhances sleep processes while improving sleep quality and quantity.
In a study in the American Journal of Physiology, men who took ipamorelin improved their slow-wave sleep, also known as deep sleep.
Slow-wave sleep is part of non–rapid eye movement (NREM) sleep commonly characterized by high-amplitude, low-frequency brain waves.
During this time, your body physically restores itself, especially your memory and immune function. In fact, about 95% of human growth hormone is produced and secreted during this sleep stage.
It also activated sleep regulatory neurons in the brains of rats.
Intracerebroventricular administration of GHRH significantly increased (P < 0.001) the amount of NREM sleep compared with the control group of rats at the beginning of the active/dark period.
A significant increase (P < 0.001) in the EEG SWA was also observed in the GHRH intracerebroventricularly-injected rats compared with the control group.
However, REM sleep amount did not change significantly (P = 0.311) following intracerebroventricular injection of GHRH.
The latency of NREM sleep onset decreased significantly (P < 0.05) after GHRH treatment (22.50 ± 2.68 min) compared with the control saline (34.17 ± 4.57 min) treatment group during the dark period.
Ipamorelin vs Tesamorelin: The Takeaway
Based on the studies we shared above, both peptides ipamorelin and tesamorelin provide similar benefits, with only subtle differences between them, including:
Structure
Tesamorelin and ipamorelin both stimulate the pituitary gland to produce more growth hormone.
However, tesamorelin consists of 44 amino acids, while ipamorelin is a pentapeptide, meaning it consists of 5 amino acids.
Benefits
Ipamorelin is commonly used for muscle growth, fat loss, and increased growth hormone secretion, while tesamorelin is used primarily to help reduce visceral fat in people with HIV-associated lipodystrophy.
This shows that tesamorelin has a very limited purpose compared to ipamorelin.
Half-Life
Tesamorelin and ipamorelin have different half-lives, influencing the excretion patterns and duration of their metabolic effects.
Tesamorelin has a half-life of approximately 1.3 to two hours compared to ipamorelin, which has a half-life of 2 to 3 hours.
Side Effects of Ipamorelin and Tesamorelin
Ipamorelin may cause reactions at the injection site, headaches, nausea, and flushing.
Less common effects include dizziness, abdominal discomfort, and fatigue.
Tesamorelin can also cause injection site reactions, along with itching, muscle aches, and swelling.
Serious side effects, though rare, include rash, hives, and difficulty breathing.
Can You Take a Combination of Tesamorelin and Ipamorelin?
Yes, a combination of Tesamorelin and Ipamorelin is possible and is often used to stimulate the pituitary gland to produce and secrete growth hormone.
The research suggests both of these peptides may work together to improve metabolic function, reduce body fat, and enhance cognition with minimal side effects.
Tesamorelin and Ipamorelin: Which One Wins?
Now that you understand how ipamorelin vs tesamorelin work, along with their unique properties and benefits, it’s time for you to decide which one best fits your current goals.
Again, if you’re looking to enhance your metabolism, build muscle growth, and reduce fat, ipamorelin is a great option.
On the other hand, if you are dealing with HIV-associated lipodystrophy, or just a lot of belly fat, tesamorelin is your best bet!
Ultimately, your choice will depend on your specific goals and health condition.
Regardless, both ipamorelin and tesamorelin are two of the best peptides you can use to improve your health.
Looking for the best, purest, and most effective tesamorelin or ipamorelin on the market?
We recommend Limitless Life Nootropics, as they have some of the best formulations of Ipamorelin and Tesamorelin on the market.
That’s not to mention Limitless offers the BEST deals on both price and peptide purity.
Use code JAY15 at the checkout cart for 15% off!
But before you start injecting these two peptides into your body recklessly, make sure you first read the Top 10 Mistakes People Make When Starting Therapeutic Peptides FREE PDF!
Seriously, this short e-book will save you a lot of wasted money and poorly spent time (not to mention preventing you from potential self-inflicted injuries).
And the emails I’ll send you after downloading the book contain an EXCLUSIVE 33% OFF code for my Peptides Demystified Course, so don’t miss out!
Raise Your Vibration To Optimize Your Love Creation!
PS — Do you want to lose weight while building lean muscle mass at the same time?
Join me and other biohackers in The Fully Optimized Health Private Membership Group to learn how you can use peptides, especially tesamorelin, and ipamorelin, to optimize your health in your 30s and beyond.
We’re excited to discuss biohacking, health, and life optimization through peptide therapy with you. See you on the other side!
